NCT02039011View on ClinicalTrials.gov

Ultra-long Acting Bronchodilator Therapy in Asthmatics

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Asthma
Interventions
DRUG

Indacaterol

Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.

DRUG

Indacaterol and tiotropium

Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.

Trial Locations (1)

DD1 3AU

Asthma and Allergy Research Group, University of Dundee, Dundee

All Listed Sponsors
collaborator

Tenovus Scotland

OTHER

lead

University of Dundee

OTHER

NCT02039011 - Ultra-long Acting Bronchodilator Therapy in Asthmatics | Biotech Hunter | Biotech Hunter